2.65
+0.08(+3.12%)
Currency In USD
Address
150 Union Square Drive
New Hope, PA 18938
United States of America
Phone
215 862 5797
Website
Sector
Healthcare
Industry
Biotechnology
Employees
70
First IPO Date
August 04, 2020
| Name | Title | Pay | Year Born |
| Mr. David P. Hochman | Founder, Chairman of the Board of Directors & Chief Executive Officer | 916,475 | 1975 |
| Mr. Andrew Lawrence Taylor M.B.A. | Chief Financial Officer | 562,409 | 1971 |
| Mr. Darren R. Sherman | Founder, President, Chief Operating Officer & Director | 914,475 | 1971 |
| Mr. Juan Lorenzo | Senior Vice President of Product Development | 0 | N/A |
| Mr. William Reed Little | Executive Vice President of Corporate Development & Strategy | 0 | 1971 |
| Mr. Mark Pomeranz | GM & Executive Vice President of Interventional Therapies | 0 | 1962 |
| Dr. Hans-Peter Stoll M.D., Ph.D. | Chief Clinical Officer | 0 | N/A |
| Dr. Yuval Hay Mika D.Sc, Ph.D. | GM & Chief Technology Officer of Bioelectronic Therapies | 0 | 1959 |
| Dr. Avraham Matityahu Fischer M.D. | Senior Vice President of Medical Affairs & Innovation | 0 | 1956 |
| Mr. Bob Laughner | Senior Vice President of Regulatory & Quality | 0 | N/A |
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.